------ =_NextPart_000_01BCD243.354FB830
Content-Type: text/plain
We have used the Dako flow products for several years and find them
to
be excellent.
We are in the process of setting up a demo with the new
"Medimachine".
I must say, our experience with any of the so called "prep"
machines,
has not been productive. However, being the eternal optimist, I
would
really like to find a DNA "mincer" that could save me from a future
carpal tunnel surgery.
Kathy Altig
PPMC
______________________________ Reply Separator
_________________________________
Subject: DAKO products experiences
Author: ,Robert Pyle [SMTP:pyle@smtpgw.kfshrc.edu.sa] at PHSOR
Date: 10/1/97 8:33 AM
I have just had a visit from our local DAKO salesman. He presented me
with a
new catalog and some advertisement information. Since DAKO is more
popular
perhaps in immunocytochemistry than it is in flow cytometry, their
prices for
their antibodies (single color, dual color and tri-color mixes) were
much more
attractive than the top three or four antibody manufacturers that we
normally
use for flow cytometry.
This leads me to ask two questions:
1. For those flowers out there using DAKO products, what have been your
experiences? Do the antibodies perform up to the standards of other
manufacturer's? How does their fluorochrome performance compare?
What
prompted you to choose DAKO over other name brands?
2. Is there anyone out their using their new "Medimachine System" for
standardization in the preparation of cell suspensions from solid
tissues.
At first glance, it looks pretty neat but I am not convinced about
the cost
effectiveness or performance. If anyone can comment on either I
would be
very interested. We do a lot of solid tissue analyses and it might
be a
real boon as a standardized approach to disaggregation.
Any and all comments are welcomed and appreciated.
Haywood Pyle
King Faisal Specialist Hospital and Research Center
Flow Cytometry Core Facility
MBC #3, Box 3354
Riyadh 11211
Saudi Arabia
e:pyle@kfshrc.edu.sa
------ =_NextPart_000_01BCD243.354FB830
Content-Type: application/ms-tnef
Content-Transfer-Encoding: base64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------ =_NextPart_000_01BCD243.354FB830--